La vendita allo scoperto per Central Plains Bancshares dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Central Plains Bancshares. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Central Plains Bancshares (NASDAQ:CPBI) Azioni, Report sulle vendite allo scoperto

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in our primary market area, as well as commercial real estate loans.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CPBI

LSAK

Questi indicatori suggeriscono che potrebbe essere il momento ideale per considerare la vendita di due titoli del settore finanziario.

Questo potrebbe essere il momento migliore per vendere queste 2 azioni

Central Plains Bancshares, Inc. - Common Stock

Central Plains Bancshares Inc

Dogecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) relatively flat performance over the past week has market commentators speculating about two important liquidation levels <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">for the meme coin</a>.
What Happened: Crypto trader Trader Tardigrade noted that Dogecoin's liquidation heatmap reveals two major liquidity targets above the current price:
<ul class="wp-block-list">
<li>$0.189 with $2.46 billion in liquidity</li>
<li>$0.1995 with $2.14 billion in liquidity</li>
</ul>
These are likely areas market makers will aim for, suggesting upward price potential.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> Liquidation Heatmap shows two significant liquidation levels above the current price. The highest level is at $0.189 with $2.46B in liquidity, and the second is at $0.1995 with $2.14B in liquidity. Market makers are aware of these levels, so you don&#39;t have to worry… <a href="https://t.co/U79beCdfpM">pic.twitter.com/U79beCdfpM</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1932056863702741095?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Hardy <a href="https://x.com/Degen_Hardy/status/1932025566821335307">observed</a> Dogecoin has returned to a strong support zone, potentially setting up a new long opportunity. The chart will be closely monitored over the next few days for confirmation.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45833498/bitcoin-ethereum-xrp-dogecoin-start-the-week-green-ahead-of-us-china-trade-talks">Bitcoin, Ethereum, XRP, Dogecoin Start The Week Green Ahead Of US-China Trade Talks</a>
Why It Matters: Pseudonymous developer PennybagsCX <a href="https://x.com/PennybagsCX/status/1932114088777203906">stated</a> that Dogechain, launched in 2022, is quietly transforming Dogecoin from a meme-based currency into a full-fledged utility ecosystem.
As an EVM-compatible blockchain, Dogechain enables smart contracts and allows DOGE to be bridged and used for transactions across a growing suite of applications. 
This includes gaming dApps, NFT marketplaces, and DeFi protocols like lending, borrowing, and yield farming, all powered by DOGE.
By expanding Dogecoin's use cases beyond simple payments, Dogechain is unlocking new opportunities for holders and helping build a vibrant, utility-driven future for the Doge community.
Coinglass data shows Dogecoin's open interest is up by 1.3% to $1.99 billion, while derivatives trading volume expanded by 25.4% in a single day. 
Options volume and options open interest expanded by 1,829% and 502.9%, respectively.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

What Is Dogecoin's Next Move? Watch These 2 Liquidation Levels, Trader Warns

AAPL

GPRO

Watching GoPro; Shares Spike Higher, Apple Announces 'VisionOS 26 supports native playback of 180-degree, 360-degree, and wide field-of-view content from Insta360, GoPro, and Canon'

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hyperlipidemia on lipid-lowering therapies, including <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">at least a statin</a>.
Hyperlipidemia&nbsp;refers to having high levels of lipids (fats) in the blood, including cholesterol and triglycerides.&nbsp;It&#8217;s a condition that can increase the risk of heart disease and other health problems.&nbsp;
The CORALreef HeFH and CORALreef AddOn trials met their primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful greater reductions in low-density lipoprotein <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45832810/merck-announces-positive-topline-results-from-the-first-two-phase-3-coralreef-trials-evaluating-en" rel="noreferrer noopener">cholesterol (LDL-C) for</a>:
<ul class="wp-block-list">
<li>Enlicitide compared to placebo (CORALreef HeFH) and other oral non-statin therapies (CORALreef AddOn).</li>
<li>There were no clinically meaningful differences in incidences of adverse events (AE) and serious adverse events (SAE) in either trial.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report" target="_blank" rel="noreferrer noopener">Merck&#8217;s Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report</a>
Results from the three Phase 3 trials in the&nbsp;CORALreef clinical development program&nbsp;will be presented at a future scientific congress.
Key takeaways from CORALreef HeFH and CORALreef AddOn studies:
<ul class="wp-block-list">
<li>CORALreef HeFH: Statistically significant and clinically meaningful reductions in LDL-C for enlicitide versus placebo in adults with heterozygous familial hypercholesterolemia (HeFH) who have a history of or are at risk for atherosclerotic cardiovascular disease (ASCVD) and are treated with a statin.</li>
<li>CORALreef AddOn: Statistically significant and clinically meaningful reductions in LDL-C for enlicitide versus ezetimibe, versus bempedoic acid and versus ezetimibe and bempedoic acid in adults with hyperlipidemia who have a history of or are at risk for ASCVD and are treated with a statin.</li>
</ul>
The efficacy and safety of enlicitide are being evaluated through the comprehensive&nbsp;CORALreef Phase 3 clinical development program, which <a target="_blank" href="https://www.merck.com/wp-content/uploads/sites/124/2025/06/CORALreef_Clinical_Trial_Explainer.pdf" rel="noreferrer noopener">aims</a> to enroll approximately 17,000 patients across several trials, including two large ongoing trials, CORALreef Lipids and CORALreef Outcomes.
Price Action: MRK stock is trading higher by 0.19% to $79.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45841878/analyst-says-newamsterdam-stock-has-over-100-upside-citing-90-success-probability-for-obicetrapib" target="_blank" rel="noreferrer noopener">Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib</a></li>
</ul>
Photo by tada images via Shutterstock

Biotech

Large Cap

Health Care

General

Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials

WIIM

OKLO

Oklo shares are trading higher after Seaport Global upgraded the stock from Neutral to Buy and announced a $71 price target.

WBD stock has given up its prior gain. Warner Bros Discovery shares were trading higher. The company announced plans to separate the company into two publicly traded companies.

Citigroup analyst Christopher Danely maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and raises the price target from $55 to $68.

Price Target

Analyst Ratings

MCHP

Citigroup Maintains Buy on Microchip Technology, Raises Price Target to $68

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has quietly joined the ranks of <a href="https://www.benzinga.com/topic/s-p-500-index">the S&amp;P 500</a>'s biggest EPS disappointments in the first quarter.
According to <a href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_060625A.pdf">FactSet</a>, Tesla landed in the bottom 10 for Actual EPS Surprise %, with its first quarter earnings missing expectations by a stark 25.3% ― a notable spot of underperformance for the EV leader.
<h2 class="wp-block-heading">Tesla's EPS Shock: A Quarter To Forget</h2>
That 25% miss puts Tesla alongside companies like Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and First Solar Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) ― far from its usual club of beats.
The data paints a different portrait than the company's headline-grabbing innovations: Tesla is being lumped in with chicken-footed performers, not the industry disruptors.
Read Also: <a href="https://www.benzinga.com/markets/asia/25/06/45834491/tesla-china-sales-surge-in-may-as-new-model-y-juniper-exported-for-the-first-time-amid-us-china-trade-war">Tesla China Sales Surge In May As New Model Y Juniper Exported For The First Time Amid US-China Trade War</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="628" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM.png" alt="" class="wp-image-943497" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM-300x233.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Can TSLA Chart Hold The Line At ~$290?</h2>
Despite the miss, TSLA remains a tale of two markets. Over the past 12 months, it's up nearly 70%, but it has stumbled –22% year-to-date, trading near $293 ― well below both its eight-day and 20-day simple moving averages (SMAs), marking a crisp bearish signal . A deeper dip below this range could signal more technical pain.
Still, Tesla stock manages mixed signals. Its 50-day SMA at $292.32 sits just under current levels, hinting at a possible floor. Meanwhile, the MACD (moving average convergence/divergence) indicator remains positive and the RSI (relative strength index) floats around neutral, signaling technical balance but little conviction .
Why the miss? Production snags. Price cuts that carved into margins. Questions around demand ― especially as EV competition heats up and macro uncertainty lingers.
That said, Tesla's long-term narrative remains intact: its energy business is scaling, global expansion continues, and recurring software and FSD revenue could restore margin optimism.
<h2 class="wp-block-heading">What&#8217;s Next For TSLA Investors?</h2>
TSLA investors may want to keep an eye on:
<ul class="wp-block-list">
<li>Tesla&#8217;s second quarter guidance and any recalibration in price strategy.</li>
<li>The stock&#8217;s technical support and whether it holds around the $290–295 zone or gives way to deeper downside.</li>
<li>A shift in narrative &#8211; if Tesla leans back into margin talk and software recurring revenues, the stock could rebound despite short-term jitters.</li>
</ul>
The investors' dilemma is clear: Tesla may be among the S&amp;P's most disappointing EPS misses in the first quarter, but is that a signal of long-term trouble &#8211; or just a short-lived blip?
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45834012/tom-lee-dismisses-worries-over-tumbling-tsla-stock-amid-elon-musk-trump-feud-tesla-still-holds-all-of-its-advantages-so-we-arent-too-concerned">Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: &#8216;Tesla Still Holds All Of Its Advantages, So We Aren&#8217;t Too Concerned&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Technicals

Tech

FSLR

NCLH

TSLA

Tesla Among S&P's Big Losers: Q1 EPS Miss Puts TSLA In Bottom 10

Morgan Stanley analyst Annelies Vermeulen maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and raises the price target from $195 to $220.

FERG

Morgan Stanley Maintains Overweight on Ferguson Enterprises, Raises Price Target to $220

Metsera, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera&#8217;s fully-biased monthly GLP-1 <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">receptor agonist candidate</a>, MET-097i.
In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45832929/metsera-announces-positive-phase-1-data-of-first-in-class-once-monthly-amylin-candidate-met-233i" rel="noreferrer noopener">with no safety signals</a>.
MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/03/44102235/why-did-metsera-stock-surge-15-on-the-worst-trading-day-of-2025-heres-what-has-happened-since-its-listing" rel="noreferrer noopener">Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here&#8217;s What Has Happened Since Its Listing</a>
Topline results from the Phase 1 trial include:
<ul class="wp-block-list">
<li>Dose-linear pharmacokinetics with an observed half-life of 19 days&nbsp;from dose to 50% of Cmax, supporting the potential for once-monthly dosing with simplified titration.</li>
<li>Body weight loss was dose-dependent, ranging from a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. 
<ul class="wp-block-list">
<li>In the trial&#8217;s single ascending dose (SAD) portion, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i.</li>
</ul>
</li>
<li>Gastrointestinal adverse events in the trial&#8217;s multiple ascending dose (MAD) portion were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid tolerance onset despite a three-fold exposure accumulation over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the trial&#8217;s SAD and the MAD portions.</li>
<li>To date, no severe or serious adverse events have been observed in the SAD or MAD portion of the trial.</li>
</ul>
Next Steps: Based on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i:
<ul class="wp-block-list">
<li>An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025.</li>
<li>Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to 12 weeks. Topline data are expected by year-end 2025 or early 2026.</li>
</ul>
The company also expects to report topline clinical data from its ultra-long-acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025.
The company anticipates that MET-034i will be the third peptide engineered with Metsera&#8217;s HALO platform to enter clinical testing.
MTSR Price Action: Metsera stock is up 13.24% at $31.13 at publication on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a></li>
</ul>
Photo: Shutterstock

Movers

MTSR

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Citigroup analyst Christopher Danely maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Neutral and raises the price target from $100 to $120.

Citigroup Maintains Neutral on Advanced Micro Devices, Raises Price Target to $120

B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and raises the price target from $48 to $54.

B of A Securities Maintains Buy on Avidity Biosciences, Raises Price Target to $54

Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in <a href="https://www.benzinga.com/general/biotech">Facioscapulohumeral Muscular Dystrophy (FSHD)</a>.
FSHD is a genetically acquired disease that leads to progressive muscle weakness&nbsp;and severely decreased functional capacity.
The data will be presented at the 32nd Annual <a href="https://www.benzinga.com/pressreleases/25/06/n45832986/avidity-biosciences-announces-positive-topline-phase-12-fortitude-data-demonstrating-consistent-im">FSHD Society International Research Congress</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44361572/avidity-biosciences-touts-positive-data-from-early-stage-duchenne-muscular-dystrophy-study-data-fda-submission-expected-by-end-of-2025" target="_blank" rel="noreferrer noopener">Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025</a>
Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD by directly targeting the disease-causing gene, double homeobox 4 (DUX4).
FSHD affects approximately 45,000 to 87,000 people in&nbsp;the United States&nbsp;and&nbsp;Europe.
Topline data from these cohorts for del-brax treated participants, compared to placebo, demonstrated:
<ul class="wp-block-list">
<li>Consistent improvement of functional mobility and muscle strength as measured by 10-meter Walk-Run test (10MWRT), Timed Up and Go (TUG), and quantitative muscle testing (QMT) as compared to placebo;</li>
<li>Consistent improvement in multiple measures of quality of life as measured by patient-reported outcomes and compared to placebo;</li>
<li>Rapid and significant reductions in levels of KHDC1L and creatine kinase, a biomarker of muscle damage.</li>
<li>Favorable long-term safety and tolerability with most adverse events (AEs) mild or moderate, with no related serious or severe adverse events and no discontinuations.</li>
</ul>
Topline data from the ongoing, fully enrolled del-brax Phase 1/2 FORTITUDE biomarker cohort are anticipated in Q2 2026.
The primary endpoint of the FORTITUDE biomarker cohort is reduction of KHDC1L, a novel DUX4-regulated circulating biomarker.
Avidity also announced that the accelerated approval regulatory pathway in the U.S. is open for del-brax and that the company has initiated the global, confirmatory Phase 3 FORWARD study in FSHD.
In a recent research note, Chardan Capital analyst Keay Nakae set a 12-month price target of $75 per share for Avidity Biosciences. The valuation stems from a Net Present Value (NPV) model of the company&#8217;s projected revenues from its RNA therapeutics pipeline, forecasted out to the year 2034.
Chardan maintained its Buy rating and increased its price forecast from $65 to $75. According to Nakae&#8217;s analysis, the valuation incorporates specific &#8220;probability of success&#8221; rates for each of Avidity&#8217;s drug candidates to account for clinical and regulatory risks.
His model assigns a 60% chance of success for the company&#8217;s FSHD candidate, 50% for its DM1 and DMD exon 44 candidates, and lower probabilities for other assets. The analyst applied a 14% Weighted Average Cost of Capital (WACC) as the discount rate to reflect the high-risk profile of the development-stage company.
Nakae also highlighted several significant risks that could impede Avidity from reaching the $75 price target. He noted that the company, which currently has no revenue-generating products, will likely require additional financing, potentially leading to shareholder dilution.
The analyst also pointed to the risks of intellectual property challenges, the critical nature of upcoming clinical trial outcomes, and the intense competition from larger, better-resourced companies in the biotechnology sector.
Price Action: RNA stock is trading lower by 11.6% to $32.03 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45797348/early-wins-regenxbios-gene-therapy-helps-duchenne-patients-walk-stronger-longer" target="_blank" rel="noreferrer noopener">Early Wins: RegenXBio&#8217;s Gene Therapy Helps Duchenne Patients Walk Stronger, Longer</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $201 to $216.

ASND

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $216

<a href="https://www.apple.com/newsroom/2025/06/macos-tahoe-26-makes-the-mac-more-capable-productive-and-intelligent-than-ever/" title="https://www.apple.com/newsroom/2025/06/macos-tahoe-26-makes-the-mac-more-capable-productive-and-intelligent-than-ever/">https://www.apple.com/newsroom/2025/06/macos-tahoe-26-makes-the-mac-more-capable-productive-and-intelligent-than-ever/</a>

Events

Apple Introduces MacOS Tahoe Which Includes Many Features In iOS; Enhancing The Calling Experience By Bringing The Phone App To Mac

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are trading higher. Stocks may be gaining as traders await details about the United States and China trade talks.

Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.89, a high estimate of $12.00, and a low estimate of $8.00. A 12.32% drop is evident in the current average compared to the previous average price target of $11.28. 
<img src="https://www.benzinga.com/files/images/story/2025/1749492062_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Arhaus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Arhaus. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arhaus compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Arhaus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Arhaus's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARHS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Arhaus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Arhaus: A Closer Look</h2>
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
<h3>Arhaus's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Arhaus showcased positive performance, achieving a revenue growth rate of 5.49% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Arhaus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Arhaus's ROE stands out, surpassing industry averages. With an impressive ROE of 1.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Arhaus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Arhaus's debt-to-equity ratio stands notably higher than the industry average, reaching 1.5. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARHS

Where Arhaus Stands With Analysts

Citigroup analyst Christopher Danely maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $110 to $130.

Citigroup Maintains Buy on Micron Technology, Raises Price Target to $130

Mizuho analyst David Belinger maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $105 to $115.

Mizuho Maintains Outperform on Walmart, Raises Price Target to $115

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $121.94, a high estimate of $146.00, and a low estimate of $99.00. This current average reflects an increase of 0.52% from the previous average price target of $121.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1749492052_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Emerson Electric among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$112.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$133.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$133.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$104.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$119.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$99.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$132.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Emerson Electric. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emerson Electric compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Emerson Electric's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Emerson Electric's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EMR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Emerson Electric analyst ratings.</a>
<h2>About Emerson Electric</h2>
Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands. Emerson organizes its business into seven segments that sell a wide range of automation software, power tools, and automation hardware such as valves, gauges, and switches. In recent years, Emerson divested its climate technology and consumer businesses to become more of a pure-play industrial automation company. The automation of a factory is an enticing long-term proposition for manufacturers, helping reduce accident rates and raise uptime and productivity.
<h3>Emerson Electric: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Emerson Electric displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.28%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Emerson Electric's ROE excels beyond industry benchmarks, reaching 2.44%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Emerson Electric's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.77, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Emerson Electric Through 17 Analysts

Investors with a lot of money to spend have taken a bullish stance on HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HCA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for HCA Healthcare.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $808,125, and 2 are calls, for a total amount of $57,170.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $325.0 to $385.0 for HCA Healthcare over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of HCA Healthcare stands at 444.86, with a total volume reaching 2,062.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in HCA Healthcare, situated within the strike price corridor from $325.0 to $385.0, throughout the last 30 days.
<h3>HCA Healthcare Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749492044_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$24.9</td>
<td>$22.6</td>
<td>$24.1</td>
<td>$385.00</td>
<td>$101.2K</td>
<td align="right">203</td>
<td align="right">92</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$20.2</td>
<td>$19.2</td>
<td>$20.2</td>
<td>$380.00</td>
<td>$101.0K</td>
<td align="right">189</td>
<td align="right">52</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.3</td>
<td>$11.0</td>
<td>$11.1</td>
<td>$365.00</td>
<td>$83.6K</td>
<td align="right">351</td>
<td align="right">163</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$23.6</td>
<td>$21.4</td>
<td>$22.3</td>
<td>$385.00</td>
<td>$82.5K</td>
<td align="right">203</td>
<td align="right">137</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.6</td>
<td>$9.1</td>
<td>$9.2</td>
<td>$350.00</td>
<td>$67.0K</td>
<td align="right">216</td>
<td align="right">76</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
After a thorough review of the options trading surrounding HCA Healthcare, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of HCA Healthcare</h3>
<ul>
<li>With a volume of 1,254,903, the price of HCA is down -3.2% at $372.06. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About HCA Healthcare</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $403.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on HCA Healthcare, which currently sits at a price target of $410. 
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $385. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on HCA Healthcare, which currently sits at a price target of $416. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Comments

Central Plains Bancshares

Vendite allo scoperto

Central Plains Bancshares (NASDAQ:CPBI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO